Details of the Drug Reposition

General Information of This Drug (ID: DM2LBC3)

Drug Name
TEW-7197   DM2LBC3
Synonyms Vactosertib
Structure
3D MOL 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Myeloproliferative neoplasm DIS5KAPA 2A20 Phase 2 [1]
Urothelial carcinoma DISRTNTN 2C92.0 Phase 2 [2]
------------------------------------------------------------------------------------
1 Phase 1/2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Myelodysplastic syndrome DISYHNUI 2A37 Phase 1/2 [3]
------------------------------------------------------------------------------------
1 Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Solid tumour/cancer DISZR48F 2A00-2F9Z Phase 1 [4]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT04103645) Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib in Treating Anemic MPN Patients. U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT04064190) Vactosertib With Durvalumab in Urothelial Carcinoma Failing Checkpoint Inhibition. U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 ClinicalTrials.gov (NCT02160106) First in Human Dose Escalation Study of TEW-7197 in Subjects With Advanced Stage Solid Tumors. U.S. National Institutes of Health.